齐拉西酮对精神病性抑郁症的增效作用

Augment effect of ziprasidone in the treatment of depression with psychotic Symptoms

目的：探讨帕罗西汀合用齐拉西酮对有精神病性症状的抑郁症的疗效和安全性。方法：对46例有精神病性症状的抑郁症的患者，随机分为合用组（帕罗西汀合用齐拉西酮）和单用组（单用帕罗西汀），疗程6周。采用汉密尔顿抑郁量表（HAMD），韦氏记忆量表修订版（WMS—RC）和治疗中出现的症状量表（TESS）进行评定。结果：两组治疗后各阶段HAMD均较治疗前明显下降（P〈0．05～0．01）；两组间比较，治疗第4、6周末，合用组评分显著低于单用组（P均〈0．05）。治疗后两组WMS—RC中各项目均明显改善（P均〈0．01），而合用组短时记忆的改善比单用组更明显（P均〈0．05）。两组不良反应比较无显著差异。结论：帕罗西汀合用齐拉西酮治疗有精神病性症状的抑郁症可增加疗效，安全性好。

Objective： To Study the efficacy and Safety of paroxetine Combined with ziprasidone for the treatment of depression with psychotic Symptoms. Methods：46patients with psychotic depression were randomly assigned to two grouds Combined groud, paroxetine combined with ziprasidone, and Control groud, paroxetine only, for 6 weeks. Hamilton depression Sales （ HAMD）, Wechsler memory Scales revised edition （WMS - RC ） and treatment emergent Symptams Scales （TESS） were used to evaluate the clinical efficacy and Safety. Results ： The Score of HAMD reduced significantly after every treatment time in two grouds （ P 〈 0.05 - 0.01 ）, with markedly lower score of HAMD in Combined groud in 4 weeks and 6 weeks treatment when Compared to that in control groud （ both 〈 0.05）. The Scores of all the items in WMS - RC improved remarkably after the treatment （ both P 〈 0.05）, with short - term memory improved observably in Combined ground Compared with that in control group（P 〈0.05）. There was no Significant difference in adverse effects between the two groups. Conclusions ： paroxetine cambined with ziprasidone in the treatment of depression with psychotic symptoms may augment the treatment effect and has a better Safety.